Hans-Peter Hartung
Voorzitter bij Neuroscience Center, Inc.
Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Garrett Herman | M | 79 |
Multiple Sclerosis International Federation
 Multiple Sclerosis International Federation Miscellaneous Commercial ServicesCommercial Services The Multiple Sclerosis International Federation is an international network of over 90 MS organizations. The non-profit company is based in London, UK. The organization provides information on MS in English, Arabic, and Spanish. | - |
| Patrick Schwarz-Schütte | M | 67 |
Heinrich-Heine-Universität Düsseldorf
| - |
| Simone Bagel-Trah | M | 55 |
Heinrich-Heine-Universität Düsseldorf
| - |
| Abdul Aziz Al-Turki | M | - |
Multiple Sclerosis International Federation
Multiple Sclerosis International Federation Miscellaneous Commercial ServicesCommercial Services The Multiple Sclerosis International Federation is an international network of over 90 MS organizations. The non-profit company is based in London, UK. The organization provides information on MS in English, Arabic, and Spanish. | - |
| Sieghardt Rometsch | M | 85 |
Heinrich-Heine-Universität Düsseldorf
| - |
| Diane Maas | F | - |
Neuroscience Center, Inc.
 Neuroscience Center, Inc. Hospital/Nursing ManagementHealth Services Neuroscience Center, Inc. provides hospital services. | - |
| Mar Tintoré | F | - |
European Committee for Treatment & Research in Multiple
| - |
| Benjamin Greenberg | M | - |
Neuroscience Center, Inc.
Neuroscience Center, Inc. Hospital/Nursing ManagementHealth Services Neuroscience Center, Inc. provides hospital services. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Neil Warma | M | 61 |
Opexa Therapeutics, Inc.
 Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | 9 jaar |
| Christopher Schelling | M | 48 |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | - |
| Timothy Barabe | M | 71 |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | 3 jaar |
| Detlev Riesner | M | 82 |
Heinrich-Heine-Universität Düsseldorf
| 37 jaar |
| Michael Richman | M | 63 |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | 11 jaar |
| Gail Maderis | F | 66 |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | 6 jaar |
| Donna R. Rill | F | 70 |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | 12 jaar |
| Scott B. Seaman | M | 68 |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | 10 jaar |
| Donald Healey | M | 62 |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | 7 jaar |
| John Dunn | M | 72 |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | - |
| Michael Puls | M | 47 |
Heinrich-Heine-Universität Düsseldorf
| 3 jaar |
| Bettina Böhm | F | 67 |
Heinrich-Heine-Universität Düsseldorf
| 4 jaar |
| Robert D. Steiner | M | 64 |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | - |
| Michelle Griffin | F | 58 |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | - |
| Tobias Georgi | M | 47 |
Heinrich-Heine-Universität Düsseldorf
| 6 jaar |
| Hubert Birner | M | 57 |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | - |
| Jason Amello | M | 55 |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | - |
| Norbert Bröcker | M | 57 |
Heinrich-Heine-Universität Düsseldorf
| 3 jaar |
| Kerstin Terhardt | F | 47 |
Heinrich-Heine-Universität Düsseldorf
| 4 jaar |
| Caroline Fichtner | M | - |
Heinrich-Heine-Universität Düsseldorf
| 3 jaar |
| Stephen Aselage | M | 73 |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | - |
| Karthik Radhakrishnan | M | 53 |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | 3 jaar |
| Harry Palmin | M | 54 |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | - |
| Luc Marengère | M | 59 |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | - |
| Kassandra Fieber | F | - |
Heinrich-Heine-Universität Düsseldorf
| 4 jaar |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Verenigde Staten | 19 | 57.58% |
| Duitsland | 11 | 33.33% |
| Verenigd Koninkrijk | 2 | 6.06% |
| Zwitserland | 1 | 3.03% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Hans-Peter Hartung
- Persoonlijk netwerk
